Collagen Peptide Hemostatic Injection for Platelet Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemorrhages, such as those occurring during surgery or trauma, are limited by the need for accessible and effective platelet transfusions, which are hindered by platelet lifespan, storage issues, contamination risks, and the ineffectiveness of existing coagulation factor concentrates, particularly in emergency situations where rapid hemostasis is crucial.
Innovation Solution
An injectable preparation comprising proteins or peptides derived from collagen, capable of inducing platelet adhesion, activation, and aggregation, which can be administered systemically to activate platelets and promote hemostasis, even in the presence of antiplatelet agents, and is designed to be easily industrialized and used at low concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platelet transfusion is used to treat hemorrhage, then hemostasis can be achieved, but platelet availability, storage conditions, contamination risks, and short shelf life limit its effectiveness
Solution Approach 1:
The patent uses collagen-derived peptides that mimic the natural ligand-binding function of platelets without requiring actual platelet transfusion. The peptides copy the essential hemostatic activity by binding to receptors on platelet surfaces, thereby reproducing the hemostatic effect of platelet transfusion while avoiding its logistical limitations
Solution Approach 2:
The patent extracts the critical functional component from whole platelets by isolating and synthesizing specific collagen-derived peptides (such as those corresponding to the RGD sequence). This extraction allows the essential hemostatic activity to be separated from the complex platelet structure, enabling storage and administration without requiring intact platelets
2Reliability
If coagulation factor concentrates are used to manage hemorrhage, then coagulation can be supported, but they do not induce platelet activation and aggregation which are key steps in stopping bleeding
Solution Approach 1:
The patent changes the molecular parameter of the treatment by using peptide fragments (specific collagen sequences) instead of whole collagen or other coagulation factors. This parameter change enables the substance to bind specifically to platelet surface receptors and trigger activation, a function that whole collagen or factor concentrates cannot perform
3Reliability
If factor VIIa is used to treat hemorrhage, then coagulation can be enhanced, but it induces high rate of thrombosis
Solution Approach 1:
The patent applies local quality by designing peptides that act specifically at the site of vascular injury where they can bind to exposed collagen and activate platelets locally. This localized action enhances coagulation where needed without systemically activating coagulation pathways that would lead to thrombosis
Solution Approach 2:
The collagen-derived peptides serve as intermediaries that bridge the gap between vascular injury (exposed collagen) and platelet activation. Rather than directly activating coagulation factors systemically like factor VIIa, the peptides mediate platelet activation locally at the injury site through specific receptor binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen-derived injectable preparation effectively stimulates platelet activity, promoting hemostasis without the risks of thrombosis, and can be used in emergency situations, including those where platelet transfusions are challenging, by activating platelets and facilitating the formation of a hemostatic plug.
Implementation Method 1
proteins or peptides inducing the adhesion and activation of platelets
Implementation Method 2
proteins or peptides inducing the adhesion and activation of platelets, or even their aggregation
Implementation Method 3
proteins or peptides inducing the adhesion and activation of platelets, or even their aggregation
Implementation Method 4
promoting hemostasis without the risks of thrombosis, and can be used in emergency situations
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to an injectable preparation comprising particles or fibrils with length less than 10 µm and at least one pharmaceutically acceptable vehicle or excipient. The particles or fibrils comprise proteins or peptides inducing adhesion and activation of the platelets, or even aggregation thereof. The preparation is useful for treating haemorrhages.